Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Chinese Patent Office
Harvard Business School
Cantor Fitzgerald
Moodys
Colorcon
Healthtrust
Medtronic
UBS

Generated: August 21, 2018

DrugPatentWatch Database Preview

HEPARIN SODIUM Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Heparin Sodium patents expire, and when can generic versions of Heparin Sodium launch?

Heparin Sodium is a drug marketed by Abraxis Pharm, Akorn, Casi Pharms Inc, Chamberlin Parenterl, Dell Labs, Fresenius Kabi Usa, Gland Pharma Ltd, Hospira, Hospira Inc, Lilly, Luitpold, Mylan Labs Ltd, Organon Usa Inc, Parke Davis, Pfizer, Pharm Spec, Pharmacia And Upjohn, Sagent Pharms, Sandoz, Shenzhen Techdow, Smith And Nephew, Solopak, Watson Labs, Watson Labs Inc, West-ward Pharms Int, Baxter Hlthcare, Mcgaw, B Braun, and Pharma Serve Ny. and is included in sixty NDAs.

The generic ingredient in HEPARIN SODIUM is heparin sodium. There are seventy-seven drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.

Drug patent expirations by year for HEPARIN SODIUM
Pharmacology for HEPARIN SODIUM

US Patents and Regulatory Information for HEPARIN SODIUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shenzhen Techdow HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 202733-001 Jun 12, 2014 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
West-ward Pharms Int HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 017007-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Labs Ltd HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 203851-001 Nov 30, 2017 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Hospira HEPARIN SODIUM heparin sodium INJECTABLE;INJECTION 088100-001 Apr 28, 1983 RX No Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Harvard Business School
Federal Trade Commission
Merck
Citi
Cipla
Accenture
Chinese Patent Office
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.